Compare BioNTech SE - ADR (BNTX) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Target Corporation — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Target Corporation trades at $153.9 (market cap $69.17B). The key difference: Target Corporation is far larger — about 3× BioNTech SE - ADR's market cap, and Target Corporation pays a 3.05% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | TGT | |
|---|---|---|
Market Cap | $23.31B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $119.34 | $152.35 |
52-Week Low | $83.89 | $83.68 |
Enterprise Value | $6.60B | $84.47B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Target Corporation (TGT) trades at $153.50, up 0.93% today, with strong technical momentum and bullish moving averages. Recent earnings beats and the appointment of a Chief AI Officer highlight operational strength. The stock is near its 52-week high, supported by positive analyst sentiment and consistent dividend payments.
Outlook remains positive with solid fundamentals and growth initiatives, though overbought technical indicators and competitive retail pressures pose risks. Revenue stability and margin improvements are key drivers, but investor caution is warranted near resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
